Vyome Holdings, Inc.
HIND Healthcare Biotechnology
In the quarter to June 2026, revenue fell 46.0%, EPS grew 100.0% and free cash flow fell 195.0%, each against the same quarter a year earlier.
Follow HIND
Vyome Holdings, Inc. (HIND) EV/Sales
As of 16 October 2026, Vyome Holdings, Inc. (HIND) trades at a EV/Sales of 139×. Over the past ten years it has ranged from −7.1× (November 2025) to 440,315,328× (June 2017); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 47.6× | (4.14%) |
| FY2024 | 49.6× | 6,769.23% |
| FY2023 | 0.7× | (43.89%) |
| FY2022 | 1.3× | — |
| FY2021 | −1.0× | — |
| FY2020 | 451,016× | (80.98%) |
| FY2019 | 2,371,429× | (37.06%) |
| FY2018 | 3,767,622× | (96.41%) |
| FY2017 | 104,890,150× | 5.78% |
| FY2016 | 99,162,853× | 118.34% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 154× | 28.09% |
| Mar 2026 | 120× | 152.45% |
| Dec 2025 | 47.6× | — |
| Sep 2025 | −6.2× | — |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | −66.3× |
| LPCN Lipocine Inc. compare | −5.2× |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| ICU SeaStar Medical Holding Corporation compare | 4.4× |
| BCDA BioCardia, Inc. compare | 30.2× |
| HIND Vyome Holdings, Inc. | 139× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)